Affiliation:
1. Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran
2. Pharmidex Pharmaceutical
Ltd., London, United Kingdom
3. Nanotechnology and Regenerative Medicine Commercialization Centre
(NanoRegMed Ltd), London BioScience Innovation Centre, London, United Kingdom
Abstract
:
Nanomachines hold promise for the next generation of emerging technology; however, nanomachines
are not a new concept. Viruses, nature’s nanomachines, have already existed for thousands
of years. In 2019, the whole world had to come together to confront a life-threatening nanomachine
named “SARS-CoV-2”, which causes COVID-19 illness. SARS-CoV-2, a smart nanomachine,
attaches itself to the ACE2 and CD147 receptors present on the cell surfaces of the lungs,
kidneys, heart, brain, intestines, testes, etc. and triggers pathogenesis. Cell entry triggers a cascade of
inflammatory responses resulting in tissue damage, with the worst affected cases leading to death.
SARS-CoV-2 influences several receptors and signalling pathways; therefore, finding a biomaterial
that caps these signalling pathways and ligand sites is of interest. This research aimed to compare the
similarities and differences between COVID-19 and its elderly sisters, MERS and SARS. Furthermore,
we glanced at emerging therapeutics that carry potential in eliminating SARS-CoV-2, and the
tissue damage it causes. Simple prophylactic and therapeutic strategies for the treatment of COVID-
19 infection have been put forward.
Publisher
Bentham Science Publishers Ltd.
Subject
General Medicine,Medicine (miscellaneous)
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献